Skip to main content
OpenTrials
Completed

NCT Number: NCT01541280

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Patients included in the study with high risk acute myeloid leukemia or myelodysplastic syndrome as defined will receive an allogeneic transplantation conditioned by either myeloablative or reduced regimen. Following allogeneic transplantation, patients will receive a maintenance regimen combining chemotherapy with azacitidine (aza) and immunotherapy with donor lymphocyte infusion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myeloid Leukemia Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndrome Myelodysplastic Syndromes Neoplasms Neoplasms by Histologic Type

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University Hospital of Nantes

Nantes, 44000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with high risk acute myeloid leukemia undergoing allogeneic transplantation with either a familial or an unrelated donor.

High risk AML is defined as :

  • AML in CR1 with unfavorable cytogenetics defined by complex caryotype, autosomal monosomy combined or not with other cytogenetics abnormalities inv(3)/t(3,3), t(6;9), t(6;11), t(11;19), del(5q), del(7q).
  • AML in CR2 or greater remission prior allogeneic transplantation
  • AML in PR or relapse prior allogeneic transplantation
  • Or Patients with high risk myelodysplastic syndrome undergoing allogeneic transplantation with either a familial or an unrelated donor.

High risk MDS is defined as :

  • MDS with intermediate-2 group and higher risk group according to IPSS criteria
  • Age 18 - 70 years.
  • Availability of an HLA identical family donor or unrelated donor with matching in 10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of 1 allele or antigen mismatch OR family donor with maximum 1 allele mismatch.
  • Conditioning regimen to allogeneic transplantation may be either myeloablative or reduced.
  • Be able to understand and sign informed consent.
  • Affiliation number to National Health Care System
  • Men and women of childbearing potential must use effective contraception during and up to 3 months after treatment.

Exclusion criteria

  • The presence of any one exclusion criteria renders the patient ineligible:
  • Patient in full relapse post-transplant (>20% blasts in the bone marrow) following allogeneic transplant
  • Documented leukemic infiltration of CNS/cerebrospinal fluid.
  • Karnofsky performance score below 60%.
  • Acute and chronic heart failure (NYHA Class III or IV) or symptomatic ischemic heart disease.

following allogeneic transplant

  • Severe liver failure (bilirubin >30 μmoles/L, SGPT > 4 X upper limit of normal).
  • Hepatic malignancy in advanced stage.
  • Severe neurological or psychiatric disorders
  • Acute GVHD grade II-III. Patient with grade I GVHD may be included (see annex 1 for GHVD grade definition).
  • Active uncontrolled infection.
  • Denied informed consent.
  • Treatment with other investigational drugs following allogeneic transplantation.
  • No effective contraception
  • Lactating females
  • Pregnant woman

Treatment and study plan

Azacitidine

Drug

Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of >15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of >1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (

DLI

Other

Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of >grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.

If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too.

Primary outcomes

  1. Evaluation of the cumulative incidence of relapse rate

    Time frame: 2 years

    An A'Hern procedure will be used (cf. 11.1): If the number of patients not relapsed at two year will be 18 or more out of 24 patients, the null hypothesis will be rejected and the relapse rate will be considered acceptable.

Secondary outcomes

  1. Evaluation of disease-free survival (DFS) at 2 years from transplantation

    Time frame: 2 years

    Kaplan-Meier method

  2. Measure the overall survival rate at 2 years

    Time frame: 2 years

    Kaplan-Meier method

  3. Cumulative incidence death from leukemia, and non relapse mortality (NRM)

    Time frame: 2 years

    cumulative incidence function for disease free survival at 2 years from transplantation, GVHD, death from leukaemia and non-relapse mortality will be estimated (patients are at risk not only for relapse but can also be "removed" from possible relapse because of competing events such as death in remission (due to infection or GVHD)).

  4. Feasibility and safety of administrating maintenance azacitidine following allogenic transplantaton

    Time frame: 2 years

    To evaluate toxicity induced by the azacitidine and DLI, different parameters will be studied:Cell Blood Count with differential, liver function tests, serum creatinine, BUN and total protein will be performed weekly from the time of initiation of azacitidine administration until completion of the last DLI. Performance Status,Acute GVHD,Bone marrow aspiration with evaluation of morphological response as well as chimerism from peripheral blood will be performed prior starting azacitidine, following 3 cycles of azacitidine and after the seventh cycle and twelfth cycle of azacitidine.

  5. Feasibility and safety of performing prophylactic donor lymphocytes infusion

    Time frame: 2 years

    The relatedness of observed toxicity to DLI will be evaluated and documented:

    • Maximum toxicity with respect to mucositis, liver, kidney, lung, heart, neurological system according to CTC criteria (cf. appendices).
    • Infections (bacteremia, fungemia, invasive fungal infection, CMV reactivation and disease, other viral reactivation or infection).
    • Grade of acute and chronic GVHD (cf. appendices); GVHD is classified according to clinical symptoms, irrespective to the time interval to DLI.
    • Bone marrow aspiration, as well as chimerism in PB.

  6. Incidence and severity of acute and chronic graft-versus-host disease

    Time frame: 2 years

    Symptoms related to GVHD should be reported within the GVHD section of the case reporting files. AE and SAE are documented in the patient's chart

    • on a daily basis, as long as the patient is on ward, and
    • on a weekly to two-monthly basis during outpatient follow up, depending on the frequency of outpatient visits on the respective patient.

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acronym: VIDAZA-DLI

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Feb 29, 2012
Registry last updated
Mar 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.